Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CCR6 | P51684 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28098177 | 1.00 | LMNA (0.74) | LMNAHSD17B10ALDH1A1L3MBTL1PTGS2 | |
| SCHEMBL890039 | 0.98 | LMNA (0.77) | LMNAHSD17B10ALDH1A1L3MBTL1PTGS2 | |
| Hydrochloric Acid SCHEMBL7981337 | 0.96 | LMNA (0.74) | LMNAHSD17B10ALDH1A1L3MBTL1PTGS2 | |
| SCHEMBL11531369 | 0.89 | ALDH1A1 (0.70) | LMNAHSD17B10ALDH1A1L3MBTL1PTGS2 | |
| Urea SCHEMBL28915393 | 0.88 | PTGS2 (0.64) | LMNAHSD17B10ALDH1A1L3MBTL1PTGS2 | |
| SCHEMBL11536760 | 0.87 | ALDH1A1 (0.65) | LMNAHSD17B10ALDH1A1L3MBTL1PTGS2 | |
| SCHEMBL15452507 | 0.87 | ALDH1A1 (0.71) | LMNAHSD17B10ALDH1A1L3MBTL1PTGS2 | |
| SCHEMBL8534360 | 0.85 | LMNA (0.71) | LMNAHSD17B10ALDH1A1L3MBTL1PTGS2 | |
| Hydrochloric Acid SCHEMBL5459649 | 0.85 | L3MBTL1 (0.73) | LMNAHSD17B10ALDH1A1L3MBTL1PTGS2 | |
| SCHEMBL15541266 | 0.85 | ALDH1A1 (0.63) | LMNAHSD17B10ALDH1A1L3MBTL1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 484 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108440433-A | The method that copper lewis acid Surfactant-Catalyzed prepares chlorination -3- substitution -2,5- diphenyltetrazolium bromides | 湖北佰智昂生物化工有限公司 | 2018-08-24 | — | — | CN | claimed |
| US-9354239-B2 | BLID; protein domain for interaction with the Bcl-2 family of proteins | WITTE-HOFFMANN CARLOS (US) | 2016-05-31 | — | — | US | claimed |
| US-9346868-B2 | BLID; a novel protein domain for interaction with the Bcl-2 family of proteins. Applications in oncology | WITTE-HOFFMANN CARLOS (US) | 2016-05-24 | — | — | US | claimed |
| EP-0720657-B1 | BIOLOGICALLY RELEVANT METHODS FOR THE RAPID DETERMINATION OF STERILITY | 3M INNOVATIVE PROPERTIES CO (US) | 2007-08-15 | — | — | EP | claimed |
| EP-0720657-A4 | BIOLOGICALLY RELEVANT METHODS FOR THE RAPID DETERMINATION OF STERILITY | 3M INNOVATIVE PROPERTIES CO (US) | 2004-08-04 | — | — | EP | claimed |
| EP-0720657-A1 | BIOLOGICALLY RELEVANT METHODS FOR THE RAPID DETERMINATION OF STERILITY | NORTH AMERICAN SCIENCE ASSOCIATES INCORPORATED (US) | 1996-07-10 | — | — | EP | claimed |
| US-5486459-A | Biologically relevant methods for the rapid determination of sterility | MEDICAL COLLEGE OF OHIO (US) | 1996-01-23 | — | — | US | claimed |
| WO-1995008639-A1 | BIOLOGICALLY RELEVANT METHODS FOR THE RAPID DETERMINATION OF STERILITY | NORTH AMERICAN SCIENCE ASSOCIATES, INC. (US) | 1995-03-30 | — | — | WO | claimed |
| EP-4712993-A2 | PHAGE THERAPY FOR ALCOHOL-ASSOCIATED HEPATITIS | The Regents of the University of California (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | PREVECEUTICAL MEDICAL INC (CA) | 2026-01-01 | — | — | US | disclosed |
| WO-2025215115-A1 | COMPOUNDS FOR USE THE TREATMENT OF CANCER, NEURODEGENERATIVE DISEASES, PSYCHIATRIC DISORDERS, INFLAMMATION, EPILEPSY AND SEIZURES | B&A ONCOMEDICAL (FR) | 2025-10-16 | — | — | WO | disclosed |
| CN-120136932-A | Metal compound capable of improving stability and preparation method and application thereof | 浙江海利得新材料股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120081885-A | Substituted phenyl glycoside compound and preparation method and application thereof | 浙江大学 | 2025-06-03 | — | — | CN | disclosed |
| CN-119950489-A | Nanoparticle for inducing iron death as well as preparation method and application thereof | 三亚中心医院(海南省第三人民医院、三亚中心医院医疗集团总院) | 2025-05-09 | — | — | CN | disclosed |
| WO-1994014064-A1 | METHODOLOGY FOR DEVELOPING A SUPERIOR LINE OF DOMESTICATED ANIMALS | UNIVERSITY OF GUELPH (CA) | 1994-06-23 | — | — | WO | disclosed |
| EP-0532636-A4 | BIS-NAPHTHALIMIDES AS ANTICANCER AGENTS | — | 1993-11-18 | — | — | EP | disclosed |
| EP-0532636-A1 | BIS-NAPHTHALIMIDES AS ANTICANCER AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-03-24 | — | — | EP | disclosed |
| WO-1991018884-A1 | BIS-NAPHTHALIMIDES AS ANTICANCER AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-12 | — | — | WO | disclosed |
| EP-0426167-A2 | Antitumor substance, process for preparing the same, and pharmaceutical composition containing the same | MEIJI SEIKA KAISHA LTD. (JP) | 1991-05-08 | — | — | EP | disclosed |
| EP-0418113-A2 | Microbiological assay kit and method for detecting antibacterial compounds | ORGENICS LIMITED (IL) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | MMP3, PEPD, MMP9 | ACHE 2551/4885LMNA 1535/4885HSD17B10 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.